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Missense mutations in the p53 tumor suppressor
inactivate its antiproliferative properties but can also
promotemetastasis through a gain-of-function activ-
ity.We show that sustained expression ofmutant p53
is required to maintain the prometastatic phenotype
of a murine model of pancreatic cancer, a highly
metastatic disease that frequently displays p53
mutations. Transcriptional profiling and functional
screening identified the platelet-derived growth fac-
tor receptor b (PDGFRb) as both necessary and suffi-
cient to mediate these effects. Mutant p53 induced
PDGFRb through a cell-autonomous mechanism
involving inhibition of a p73/NF-Y complex that re-
presses PDGFRb expression in p53-deficient, nonin-
vasive cells. Blocking PDGFRb signaling by RNA
interferenceorbysmallmolecule inhibitorsprevented
pancreaticcancercell invasion in vitroandmetastasis
formation in vivo. Finally, high PDGFRb expression
correlates with poor disease-free survival in pancre-
atic, colon, and ovarian cancer patients, implicating
PDGFRb as a prognostic marker and possible target
for attenuating metastasis in p53 mutant tumors.
INTRODUCTION
Mutations in the p53 tumor suppressor gene represent the most
common genetic lesions in cancer (Freed-Pastor and Prives,
2012). Functional studies indicate that wild-type p53 possesses382 Cell 157, 382–394, April 10, 2014 ª2014 Elsevier Inc.a series of antiproliferative activities that limit the proliferation
and survival of premalignant cells. p53 exerts these activities,
at least in part, through its ability to bind DNA in a sequence-
specificmanner to regulate gene expression, and the vastmajor-
ity of mutations that occur in human tumors disable this property
of p53 and, consequently, its antiproliferative effects.
p53 mutations typically occur within the DNA-binding region
and involve either DNA contact residues or residues important
for conformational structure, both resulting in loss of DNA bind-
ing (Joerger and Fersht, 2007). Because p53 functions as a tetra-
meric transcription factor, mono-allelic p53 mutations can exert
dominant-negative effects on a coexpressed wild-type p53
protein. p53 activates E3 ubiquitin ligases that feed back to
trigger p53 destruction and its rapid turnover; however, p53
missense mutants defective in regulating gene expression lead
to the stable accumulation of the variant proteins (Oren
and Rotter, 2010). Interestingly, genetically engineered mice
harboring common p53 point mutations develop more aggres-
sive and metastatic tumors compared to those arising in their
p53 heterozygous or null counterparts (Lang et al., 2004; Olive
et al., 2004, Hanel et al., 2013), suggesting that the mutant forms
of p53 exert gain-of-function activities independent of their
effects on wild-type p53. Accordingly, human tumors with
mutant p53 are associated with poor patient prognosis (Soussi
and Be´roud, 2001) and drug resistance (Masciarelli et al., 2013).
Recently, targetingmutant p53 function has been proposed as
an antimetastatic measure. As p53 mutant proteins have to date
proved undruggable (Levine and Oren, 2009; Lehmann and Pie-
tenpol, 2012), efforts have focused on identifying the underlying
mechanisms that mediate its effects. Such efforts have identified
proteins involved in integrin recycling (Muller et al., 2009), the
mevalonate pathway (Freed-Pastor et al., 2012), or microRNA
(miRNA) biogenesis (Su et al., 2010) as potential mediators of
mutant p53 action in invasion and metastasis. So far, most
studies have been performed in breast cancer, and the proposed
mechanisms do not necessarily validate across cancer types.
These observations underscore the importance of the cellular
context in assessing mutant p53 action and highlight the poten-
tial complexity of the effector network.
Pancreatic ductal adenocarcinoma (PDAC) is one cancer type
in which mutant p53 impacts disease progression. PDAC arises
from indolent pancreatic intraepithelial neoplasias (PanINs) that
frequently go undetected and persist for many years. However,
the conversion of PanINs to highly aggressive, frankly invasive
andmetastatic PDACs, in which p53 is mutated in 75%of cases,
carries a dire prognosis because of late-stage detection, the
presence of metastases, and ineffective treatment options (Li
et al., 2004). Even those patients with a surgically approachable
pancreatic lesion develop recurrent and metastatic disease after
local tumor resection (Hidalgo, 2010). Consistent with a role for
mutant p53 in this process, mice harboring pancreatic cancers
driven by oncogenic Kras and a mutant p53 allele show more
metastases compared to identical mice harboring a p53 null
allele (Morton et al., 2010). However, it is not known whether
mutant p53 is needed to sustain the metastatic phenotype and
how it is regulated. Such information would produce insights
into p53 action and validate mutant p53 as a therapeutic target.
In this study, we combined several orthogonal approaches
and models to systematically explore the molecular basis
whereby mutant p53 promotes invasion and metastasis in
PDAC and the clinical implications of its effects. These studies
identified the platelet-derived growth factor receptor b
(PDGFRb) as necessary and sufficient to mediate the effects of
mutant p53 on invasion and metastasis in both a murine model
and human PDAC cells. Further, we identified elevated PDGFRb
expression as an indicator of poor metastasis-free survival in
human PDAC patients. Taken together, our data identify a
key mediator of mutant p53 activity and suggest that PDGFRb
inhibitors may act as antimetastatic agents in some patients
with tumors expressing mutant p53.
RESULTS
Sustained Expression of Mutant p53 Is Required for the
Invasive Phenotype of Pancreatic Cancer Cells
Genetically engineered mouse models of pancreatic cancer
harboring a latent oncogenic Kras allele (lox-stop-lox KrasG12D),
a latent mutant p53R172H, and a tissue-specific Cre recombinase
(Pdx1-Cre), also known as KPC mice, develop highly metastatic
pancreatic cancer that faithfully mimics the human disease
(Hingorani et al., 2005). To understand the impact of p53 muta-
tions on cell invasion and metastasis in this well-defined genetic
system, we employed a murine KPC pancreatic cancer cell line
that lost the remaining p53 wild-type allele during disease
progression (Morton et al., 2010). The behavior of KPC cell
lines stably expressing small hairpin RNAs (shRNAs) targeting
(mutant) p53, or control shRNAs targeting Renilla (KPC+sh.Ctrl),
were compared to one another and to a p53 null KPflC cell line
(from a Pdx-Cre, LSL-KrasG12D/+, LSL-p53loxP/+) expressing the
control shRNA (KPflC+sh.Ctrl).We confirmed that KPC+sh.Ctrl cells expressing mutant
p53 efficiently migrated in scratch-wound assays. This motility
depended on mutant p53, as mutant p53 knockdown in
KPC+sh.p53 cells reduced motility similarly to p53/ KPfl
C+sh.Ctrl cells (Figure 1A). Next, we examined the invasive
capacity of KPC cells into collagen gels in an inverted invasion
assay. The presence of mutant p53 in KPC+sh.Ctrl cells
enhanced invasiveness, which was significantly abrogated
upon p53 knockdown (Figure 1B). The ability of mutant p53 to
drive cell invasion was also evident following enforced expres-
sion of p53R175H and p53R273H, two mutants frequently found
in human PDAC, in KPflC cells. This result indicates that the
differences in invasiveness of KPC and KPflC cells depend on
mutant p53 and were not acquired during generation and
selection of cell populations expressing shRNAs or through
RNAi off-target effects.
To test whether mutant p53 expression was required to
sustain the metastatic potential of KPC cells, we orthotopically
injected KPC+sh.Ctrl and KPC+sh.p53 cells into the pancreata
of athymic mice and scored the number of metastases formed
in both lung and liver, the most common sites of pancreatic can-
cer spread in patients. Although the primary tumor burden was
independent of p53 status, tumors originating from KPC+sh.Ctrl
cells expressing mutant p53 were significantly more metastatic
than those in which mutant p53 was silenced, and metastases
in the lung and liver were detected to a greater extent in mice
that had been injected with cells expressing mutant p53 (Fig-
ure 1C). Together, these results demonstrate that mutant p53
can contribute to PDAC invasion and metastasis and that inhib-
iting its activity can have an antimetastatic effect.
Transcriptional Profiling and Functional Screening
Identify PDGFRb as a Downstream Mediator of Mutant
p53 in Murine Pancreatic Cancer
To gain insight into how mutant p53 mediates the invasive
phenotype of PDAC, we performed genome-wide transcriptome
profiling of KPC cells by RNA sequencing (RNA-seq). Four
days following knockdown of mutant p53 in three independent
clonal KPC populations, we observed a complex pattern of
gene expression changes compared to three independent
KPC+sh.Ctrl cell lines. We identified 441 genes either signifi-
cantly up- or downregulated upon shRNA-mediated depletion
of endogenous mutant p53 (Figure 2A; Figure S1A available
online). Ingenuity pathway analysis revealed that 20% of the
affected genes fall into the functional class of ‘‘cellular move-
ment,’’ supporting our experimental observations that mutant
p53 can govern the invasive phenotype of pancreatic cancer
cells (Figures 2B and S1C).
To facilitate the identification of mediators of mutant p53
activity, we focused on genes whose expression was positively
regulated by mutant p53, as such molecules might both mediate
effects of mutant p53 and be targets for pharmacological inhibi-
tion. Therefore, we generated pools of 3–6 shRNAs targeting
individual upregulated genes, and we screened them one-by-
one to identify those that phenocopied the decreased invasion
seen upon downregulation of mutant p53 (Table S1). We identi-
fied three genes whose knockdown abrogated invasion driven
by mutant p53 (Figure 2C). SLC40A1 is a cell membrane proteinCell 157, 382–394, April 10, 2014 ª2014 Elsevier Inc. 383
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Figure 1. Depletion of Mutant p53 Abro-
gates Invasiveness of Pancreatic Cancer
Cells
(A) Quantification of wound distances in scratch-
wound assays from 0, 3, 7, and 10 hr after
wounding of KPC cells stably expressing a non-
targeting control shRNA (sh.Ctrl) or a shRNA-
targeting mutant p53 (sh.p53) or KPflC cells
stably expressing a sh.Ctrl (left panel). Data
presented as mean ± SD. ***p < 0.001. Repre-
sentative phase contrast images from live cell
recordings of each condition are shown at 0 and
10 hr (right panel).
(B) KPC+sh.p53, +sh.Ctrl, and KPflC cells
expressing the GFP control and mutant p53
(175H and 273H) vector were allowed to invade
into collagen for 72 hr before quantification as
described in the Experimental Procedures (left
panel). The average of invaded cells from nine
replicates ± SD is shown. A representative result
of three repeated experiments is shown.
**p < 0.01, ****p < 0.0001. Representative three-
dimensional (3D) reconstructions of each condi-
tion are shown (right panel). Cells were stained
for F-actin (red) and DAPI (blue); the dashed line
indicates the approximate position of the Trans-
well membrane; and the arrow indicates the
direction of movement.
(C) KPC+sh.p53 or +sh.Ctrl cells were orthotopi-
cally injected into the pancreata of athymic mice.
When symptomatic, mice were euthanized, and
metastatic spread in lung and liver was quantified
by counting GFP-positive macroscopic nodules
(left panel). Data presented as mean ± SD. *p <
0.05, **p < 0.01. Panels show representative
merged brightfield/GFP images from lung and
liver (right panel).that has been shown to mediate cellular iron efflux (Montalbetti
et al., 2013); SNED1 is a stromal marker that induces cisplatin-
resistance in head and neck squamous carcinoma (Longati
et al., 2013); and PDGFRb is a receptor tyrosine kinase that
mediates PDGF-regulated proliferation, survival, and chemo-
taxis (Dai, 2010).
Oncogenic properties of mutated or amplified PDGFRa have
been extensively studied in several tumor types, whereas
PDGFRb has been exclusively linked to tumor angiogenesis via
paracrine effects (Pietras et al., 2003; Cao et al., 2004). Based
on our screening results, we hypothesized that PDGFRb may
also have a cell-autonomous impact on cell invasion in pancre-
atic cancer. First, we verified by qRT-PCR and western blotting
that PDGFRbmRNA and protein were reduced upon knockdown
of mutant p53 (Figures 2D and 2E). Expression of mutant p53
correlated with high PDGFRb expression levels and also with
the expression of key downstream mediators of the PDGFRb
signaling cascade (Figure S1B).384 Cell 157, 382–394, April 10, 2014 ª2014 Elsevier Inc.We next examined the effects of
depleting each PDGFR isoform on the
invasive potential of KPC cells in vitro
(Figure 3A). Although knockdown ofPDGFRa had no effect, depletion of PDGFRb decreased the
ability of KPC cells to invade (Figure 3B). Conversely, over-
expression of PDGFRb in p53/ KPflC enhanced cell migration
and invasion, similarly to cells overexpressing mutant forms
of p53 (Figure S2A). Reduced levels of PDGFRb in KPC
cells neither altered the rate of cell proliferation (Figure S2B)
nor led to a competitive proliferative disadvantage over
KPC cells expressing high PDGFRb levels (Figure S2C). When
GFP-positive KPC+sh.PDGFRb cells were mixed with dsRED-
positive KPC+sh.Ctrl cells and injected subcutaneously into
athymic mice, the GFP:dsRED ratio of pre-injected cells
was maintained in the established tumors, indicating that
increased PDGFRb levels did not confer a selective advantage
to tumor cell proliferation at the site of injection (Figure S2D).
Thus, cell-autonomous activity of PDGFRb is not required
for the proliferation and tumorigenic potential of p53 mutant
murine cancer cells but specifically impacts their invasive
potential.
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B Figure 2. Identification of PDGFRb as a
Downstream Mediator of Mutant p53 in
Regulating Cell Invasion
(A) Schematic workflow of RNA sequencing.
(B) Ingenuity pathway analysis (Ingenuity Systems,
http://www.ingenuity.com). Bars (p < 0.05) repre-
sent molecular and cellular functions that are
significantly changed following mutant p53
depletion.
(C) One-by-one invasion assay screen. Quan-
tification of invaded KPC cells infected with
individual shRNA-pools (3.6 shRNAs/gene)
targeting the top 40 upregulated genes
identified by RNA-seq. Data presented as
mean ± SD.
(D) qRT-PCR for PDGFRb in KPC+sh.p53 (2 or 3)
or +sh.Ctrl cells. Data presented as mean
normalized PDGFRb expression ± SD of tripli-
cate samples. **p < 0.01, ***p < 0.001. A repre-
sentative result of three repeated experiments is
shown.
(E) Western blotting analysis of PDGFRb,
p53, and actin in sh.p53- or sh.Ctrl-ex-
pressing KPC cells. The two bands of PDGFRb
represent differentially glycosylated forms of the
protein.
See also Figure S1 and Table S1.PDGFRb Mediates Mutant p53 Action in Human Cancer
Cells
To determine if the mutant p53-PDGFRb signaling axis acts
in human cancer cells, we analyzed PDGFRb expression
levels in a panel of human pancreatic cancer cell lines. As
in our model, PDGFRb mRNA levels were significantly higher
in cells expressing mutant p53 compared to those in cell
lines that maintained or lost the wild-type p53 allele (Figure 3C).
Furthermore, knockdown of mutant p53 in Miapaca2,
BXPC3, CFPAC, and A2.1 cell lines (carrying the 248W,
220C, 242R, and 155P alleles, respectively) decreased
PDGFRb mRNA levels to varying degrees (Figure 3D). Knock-
down of mutant p53 also decreased PDGFRb expression in
several human colon (SW620, p53273H/P309S), lung (H1975,
p53273H), and breast (MDA-MB-231, p53280K) cancer cell
lines (Figure S2E). Thus, the ability of mutant p53 to induce
PDGFRb levels is not strictly confined to a particular p53 allele
or tumor type.
We further analyzed the functional connection between
mutant p53 and PDGFRb in promoting the invasiveness of
human PDAC lines. Consistent with our studies in mouseCell 157, 382–3PDAC lines, knockdown of either mutant
p53 or PDGFRb reduced invasiveness
of the A2.1 pancreatic cancer cell line
(Figure 3E). Conversely, overexpression
of PDGFRb in the human p53/ ASPC
pancreatic cancer cell line enhanced
invasion compared to cells infected with
a GFP control vector (Figure S2F).
Collectively, these results confirm that
upregulation of the PDGFRb receptoris important for the action of mutant p53 in PDAC and possibly
other tumor types.
Mutant p53 Disrupts the p73/NF-Y Complex to Mediate
PDGFRb Expression and Tumor Cell Invasion
Several pro-oncogenic properties of mutant p53 depend on its
ability to physically interact with and inhibit the p53 family
members, p63 and p73 (Li and Prives, 2007). Because a previous
report indicated that p73 can repress the transcription of
PDGFRB (Hackzell et al., 2002), and because our KPC cells
expressed p73, but not p63, as determined by RNA-seq (data
not shown), we aimed to understand whether the physical inter-
action of mutant p53 with p73 might impair the ability of p73 to
negatively regulate the expression of PDGFRb.
First, we verified the interaction between p73 and mutant p53
proteins by reciprocal coimmunoprecipitation (Figure 4A), and,
consistentwithprevious reports, p73binding toa ‘‘conformation’’
p53 mutant (R175H) appeared stronger than to a ‘‘DNA-binding’’
p53 mutant (R273H) (Gaiddon et al., 2001; Muller et al., 2009).
Next, using a luciferase reporter driven from the PDGFRB pro-
moter, we confirmed that overexpression of p73 in KPflC cells94, April 10, 2014 ª2014 Elsevier Inc. 385
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Figure 3. Depletion of Mutant p53 in Murine
and Human Pancreatic Cancer Cells
Decreases PDGFRb Expression Levels to
Enhance Cell Invasion
(A) PDGFRa, PDGFRb, and actin levels of KPC
cells infected with shRNAs targeting PDGFRa,
PDGFRb, or a nontargeting control (Ctrl) as
determined by western blotting.
(B) Quantification of the invasion into collagen of
cell lines from (A), compared to KPC+sh.p53. Data
presented as mean ± SD. **p < 0.005.
(C) qRT-PCR for PDGFRb in 21 human pancreatic
cancer cell lines of different p53 status. Data
presented as mean normalized PDGFRb expres-
sion ± SD. *p < 0.05.
(D) qRT-PCR for PDGFRb in the human pancreatic
cancer cell lines Miapaca2, BXPC3, CFPAC, and
A2.1 expressing sh.p53 or sh.Ctrl. Data presented
as mean normalized PDGFRb expression ± SD.
*p < 0.05, ***p < 0.001. p53 mutation of each cell
line as indicated. p53 and actin levels were
determined by western blotting (lower panel).
(E) Quantification of invasion of human A2.1 cells
infected with sh.PDGFRb, sh.p53, or sh.Ctrl (right).
Data presented as mean ± SD. **p < 0.005, ***p <
0.001, ****p < 0.0001. Representative 3D re-
constructions of invaded cells are shown (left).
See also Figure S2.decreased transcriptional activity of PDGFRB and, conversely,
that knockdownof endogenous p73 increased luciferase expres-
sion (Figures 4C and S3A). We also observed a similar increase
in luciferase signal upon overexpression of two distinct forms
of mutant p53 in KPflC cells (Figure 4C) as well as a significant
decrease upon depletion of mutant p53 or overexpression of
p73 in KPC cells (Figure S3C). Importantly, depletion of endo-
genous p73 in KPC cells expressingmutant p53 did not enhance
the transcription of PDGFRB (Figure S3C), indicating that the re-
pressing activity of p73 is regulated by its interaction with mutant
p53. Hence, mutant p53 cancels the ability of p73 to repress
PDGFRb transcription, leading to an increase in its expression.
To better understand how p73 represses PDGFRB transcrip-
tion, we performed chromatin immunoprecipitation (ChIP) anal-
ysis in KPflC cells but failed to detect direct binding of p73 to
the PDGFRB promoter (data not shown), a result consistent
with previous reports (Matys et al., 2006). Nevertheless, pro-
moter analysis of PDGFRB (Transfec, Biobase) identified a386 Cell 157, 382–394, April 10, 2014 ª2014 Elsevier Inc.conserved CCAAT binding motif for
NF-Y, a well-characterized heterotrimeric
transcriptional activator (NF-YA, NF-YB,
and NF-YC) of PDGFRB, where the
NF-YB subunit interacts with p73 but is
devoid of transcriptional activity (Ballagi
et al., 1995; Ishisaki et al., 1997; Serra
et al., 1998). We verified NF-Y binding to
the PDGFRB promoter by use of ChIP
analysis (Figure 4B). Remarkably, this
binding was prevented by p73 overex-
pression, suggesting that the p73/NF-Yinteraction hampers its ability to bind and activate the PDGFRB
promoter (Figure 4B). Indeed, when we immunoprecipitated p73
in KPflC cells, we detected direct binding of NF-YB to p73 (Fig-
ure 4A). This interaction was abrogated upon expression of
mutant p53, indicating that it disrupts or interferes with the for-
mation of the inhibitory p73/NF-Y complex (Figure 4A).
Next, we tested whether the repressive action of p73 on
PDGFRB transcription was mediated by NF-Y and modulated
by mutant p53, and we considered the implications of this
regulatory circuit for invasion. Interestingly, the ability of p73
overexpression to inhibit the PDGFRB-luc reporter was abol-
ished by depletion of NF-YB (Figures 4D and S3B), and NF-YB
knockdown suppressed the ability of mutant p53 to enhance
PDGFRb expression in KPflC cells (Figure S3D). As expected,
p73 overexpression reduced the invasive potential of KPflC cells,
whereas knockdown of p73 or overexpression of mutant p53
significantly increased invasiveness (Figure 4E). Conversely, as
occurred in mutant p53 cells following p73 overexpression,
AC D
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B Figure 4. Mutant p53 Sequesters p73 to
Impede the Repressive Function of the
p73/NF-Y Complex on the PDGFRB Pro-
moter
(A) KPflC cells stably expressing a GFP, p53
R175H,
or p53R273H vector were transfected with HA.
TAp73a. Either p53 or HA was immunoprecipi-
tated, and the expression of HAp73a, p53, or
NF-YB was determined in both the input (10% of
lysates) and immunoprecipitation.
(B) Chromatin immunoprecipitation (ChIP) using
NF-YB antibodies in KPflC cells stably expressing
sh.Ctrl, sh.NF-YB, or HAp73a. Values are means ±
SD. **p < 0.01.
(C) KPflC cells stably expressing a GFP, HAp73a,
p53R175H, or p53R273H vector or sh.p73 (1 or 2)
were cotransfected with the PDGFRB promoter
luciferase construct and renilla luciferase vector.
Firefly-luciferase activity of GFP vector cells was
set to one. Values are relative Firefly luciferase
(Fluc) units normalized by renilla expression
(Rluc) ± SD of quadruplicate samples. **p < 0.01,
***p < 0.001. A representative result of three
repeated experiments is shown.
(D) KPflC+GFP cells and KPflC+HAp73a cells
superinfected with sh.Ctrl or sh.NF-YB (1 or 2)
were cotransfected with the PDGFRB promoter
luciferase construct and renilla luciferase vector.
Luciferase activity was measured as described
above. ***p < 0.001.
(E) Quantification of invasion of the same cells as in
(C). Data presented asmean ± SD. *p < 0.05, ***p <
0.001, ****p < 0.0001.
(F) Quantification of invasion of same cells as in (D).
Data presented as mean ± SD. **p < 0.01, ****p <
0.0001.
(G) Scheme summarizing the mechanism of action
of mutant p53 in promoting invasiveness.
See also Figure S3.depletion of p53 also reduced the invasive behavior in KPC cells
(Figure S3E). Finally, NF-YB knockdown restored the invasive
potential of KPflC cells that overexpressed p73 (Figure 4F) and
suppressed the ability of mutant p53 to enhance cell invasion
(Figure S3F). Together, these results support a model in which
mutant p53 promotes invasion in pancreatic cancer cells, in
part, via an indirect mechanism that depends on its ability to
enhance PDGFRb expression through the disruption of the inhib-
itory p73/NF-Y complex (Figure 4G).
Modulation of PDGFRb Expression Levels Mediates the
Phenotypic Effects of Mutant p53 Depletion In Vivo
Following the observation that p53 mutants induce the expres-
sion of PDGFRb to promote cell invasion in PDAC cultures,Cell 157, 382–3we investigated whether PDGFRb levels
regulate metastatic behavior of PDAC
cells in mice. To this end, we performed
a lung colonization assay by injecting
KPC+sh.p53, KPC+sh.PDGFRb, KPC+
sh.PDGFRa, or KPC+sh.Ctrl cells intrave-
nously via the tail vein into athymicmice, and then we quantified the number of colonies formed
in the lungs. We found that, whereas KPC+sh.Ctrl and
KPC+sh.PDGFRa cells expressing mutant p53 formed tumor
nodules in the lungs at high frequency, PDGFRb depletion signif-
icantly reduced the number of lung colonies, phenocopying the
antimetastatic effect observed upon knocking down mutant
p53 (Figures 5A and S4A). However, depletion of PDGFRb did
not affect the size of the metastatic foci, suggesting that
PDGFRb does not alter their capacity to grow and proliferate in
a new environment (Figure S4B). In whole-lung sections, GFP-
positive signals coincided with metastatic nodules, indicating
that metastases formed from cells expressing shRNAs and likely
not from the proliferation of tumor cells that lost shRNA expres-
sion (Figure S4C).94, April 10, 2014 ª2014 Elsevier Inc. 387
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Figure 5. PDGFRb Mediates Mutant p53
Prometastatic Function In Vivo
(A) Lung colonization assays after tail vein injection
of KPC cells +sh.PDGFRa, +sh.PDGFRb (1 or
2), +sh.p53, or +sh.Ctrl. The total number of lung
metastatic nodules in individual mice (n > 5) was
counted on serial histological sections (left). Data
presented as mean ± SD. **p < 0.01, ****p <
0.0001. Representative merged brightfield/GFP
images of whole lung from indicated mice (right).
(B) MTS assay (E490) of murine KPC and human
A2.1 cells treated with crenolanib with various
doses for 72 hr. Normalized values presented as
mean ± SD from quadruple replicates.
(C) Immunoprecipitation of PDGFRb from KPC
cells stimulated with 50 ng/ml PDGF-BB after
crenolanib or DMSO treatment for 4 hr. Protein
levels of PDGFRb, phospho-Tyrosine, and tubulin
were determined by western blotting.
(D) Quantification of invasion of murine KPC and
human A2.1 treated with either DMSO or cren-
olanib at 300 nM (left). Data presented as mean ±
SD. **p < 0.01, ***p < 0.001. Representative 3D
reconstructions of invaded cells are shown (right).
(E) Lung colonization assays after tail vein injection
of crenolanib- (300 nM) or DMSO-treated KPC
cells. Representative merged brightfield/GFP
imaged of whole lung and hematoxylin and eosin
(H&E) stains of pulmonary lobes are shown (left).
Quantification of the total number of lung meta-
static nodules in individual mice (n > 6) (right). Data
presented as mean ± SD. **p < 0.01. Scale bars
represent 1,000 mm.
See also Figure S4.We next sought to examine whether pharmacologic inhibition
of the PDGFRb pathway recapitulates the effects of PDGFRb or
mutant p53 depletion (Figures 5A and S4A). We used the
compound crenolanib, a small molecule inhibitor of type III tyro-
sine kinases, potent against PDGFRa, PDGFRb, and FLT3, but
not against other known receptor tyrosine kinases (VEGFR,
FGFR), serine/threonine (RAF), or tyrosine kinases (ABL1) (Lewis
et al., 2009). We assessed the potency and efficacy of crenolanib
on inhibiting the viability of murine KPC and human A2.1 pancre-
atic cancer cells and found that the dose-response patternswere
comparable between the two cell lines, with IC50 values of 13.1
and8.5mM, respectively (Figure 5B). Strong inhibition of PDGFRb
activity, as measured by phospho-PDGFRb, was achieved in
both cell lines at 0.3mM, adose atwhich no toxicitywas observed
(Figures 5C and S4D). Time-course experiments revealed that388 Cell 157, 382–394, April 10, 2014 ª2014 Elsevier Inc.strong target inhibition was achieved
within 10 min of drug treatment (Fig-
ure S4E). Accordingly, crenolanib treat-
ment of KPC and A2.1 cells substantially
reduced invasion relative to that seen
with cells treated with DMSO (Figure 5D).
To test whether crenolanib can sup-
press metastasis, KPC cells were pre-
treated with the drug overnight and
injected intravenously into recipient micethat were subsequently assessed for colony formation in the
lung. Although drug treatment had no effect on the viability of
the injected cell population, mice injected with drug-treated
KPC cells showed significantly fewer lung nodules compared
to controls pretreated with DMSO (Figures 5E and S4F).
Conversely, the same concentration of crenolanib did not reduce
the metastatic potential of KPflC cells in a lung colonization
assay, suggesting that PDGFRb acts autonomously in KPC cells
to potentiate cell invasion and metastasis (Figure S4G). Further
supporting this notion, conditioned media from KPC cells and
most human pancreatic cell lines tested triggered PDGFRb
phosphorylation in serum-starved 3T3 cells, indicating pancre-
atic cancer cells can provide a source of PDGF ligand that could
trigger autocrine activation of PDGFRb (Figure S4H; data not
shown). Therefore, abrogation of this signaling by RNAi or small
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Figure 6. Imatinib Reduces the Incidence of
Metastasis in KPC Mice through PDGFRb
Inhibition
(A) Immunoprecipitation of PDGFRb from KPC
cells stimulated with 50 ng/ml PDGF-BB after im-
atinib or DMSO treatment for 4 hr. Protein levels of
PDGFRb, phospho-Tyrosine, and tubulin were
determined by western blotting.
(B) Lung colonization assays after tail vein
injection of imatinib- (3 mM) or DMSO-treated
KPC cells. Representative merged brightfield/
GFP images of whole-lung and H&E stains of
pulmonary lobes are shown. Arrows indicate
metastases (middle panel). Quantification of the
total number of lung metastatic nodules in indi-
vidual mice (n > 5) (right panel). Data presented
as mean ± SD. **p < 0.01. Scale bars represent
100 mm.
(C) Weight of pancreatic tumors of KPC mice
treated with vehicle or imatinib at time of death.
(D) Quantification of the number of mice with
metastatic disease at the time of death. Values are
percentages of the total number of mice in each
cohort. Colored columns represent mice with
metastases (METS), and white columns represent
disease-free (DF) animals.
(E) Quantification of the number of mice with lung,
peritoneal (Peri.), or liver metastatic disease at the
time of death. Values are percentages of the total
number of mice in each cohort.
(F) Representative H&E stains of harvested organs
(primary tumor, lung, liver, or peritoneal tissue)
from vehicle and imatinib-treated animals. Scale
bars represent 100 or 50 mm (insets).
(G) Representative immunofluorescence images
of pancreatic tumors of vehicle- or imatinib-
treated KPC mice. DAPI, blue; CK8, red; and
pPDGFRb, green. Scale bars represent 100 mm.
See also Figure S5.molecule inhibitors leads to a significant reduction of invasion
and metastasis driven by mutant p53 in vitro and in vivo.
Imatinib Inhibits the Development of Metastases in a
PDAC Mouse Model by Targeting PDGFRb
The results described above imply that pharmacologic inhibition
of PDGFRb could have antimetastatic effects. We therefore
sought to determine whether PDGFRb inhibition prevents
metastasis in KPC mice that develop metastatic disease with a
variable latency of 3 to 10 months in 50%–80% of animals (Hin-
gorani et al., 2005). For long-term treatment of KPC mice, we
decided to use FDA-approved imatinib, a potent inhibitor of
PDGFRb, c-KIT, and BCR-ABL activity. Notably, the c-KIT and
BCR-ABL kinases have not been linked to PDAC development
(Jones et al., 2008).Cell 157, 382–3Inhibition of PDGFRb by imatinib in
KPC cells strongly reduced PDGFRb
tyrosine phosphorylation at 3 mM (Fig-
ure 6A), a dose of the drug that is signifi-
cantly lower than that required to inhibit
cell proliferation (IC50 of 29.7 mM) (Fig-ure S5A). Nonetheless, imatinib treatment significantly reduced
the invasive potential of KPC cells in vitro (Figure S5B). More
importantly, pretreatment of KPC cells with imatinib decreased
their potential to colonize the lungs of recipient athymic mice
to a similar extent as that seen upon crenolanib treatment
(Figure 6B).
We next treated KPC mice with imatinib to assess its effects
on metastasis. To this end, mice were treated with a dose of
50 mg/kg imatinib by oral gavage twice daily, a regimen previ-
ously shown to produce therapeutic concentrations of imatinib
in mice (Wolff et al., 2003). Treatment was initiated in mice of
8 weeks of age, a time at which KPC mice have developed pre-
neoplastic lesions (Hingorani et al., 2005), and mice were moni-
tored until they became symptomatic. Imatinib had no impact on
tumor volume in the pancreas or overall survival, suggesting that94, April 10, 2014 ª2014 Elsevier Inc. 389
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Figure 7. High PDGFRb Expression in
Human Pancreatic and Colorectal Cancer
Correlates with Reduced Metastases-free
Survival
(A) Kaplan-Meier survival curves of 98 pancreatic
cancer patients (clinical variable = DFS) as a
function of PDGFRb-high versus PDGFRb-low
expressing tumors.
(B) Box plot of PDGFRb expression versus tumor
grade of pancreatic tumors (n = 98). Data pre-
sented as mean ± SD.
(C) Clinicopathologic analysis of vascular space
invasion of pancreatic cancer patients stratified
by the expression levels of PDGFRb in the primary
tumor.
(D) Stratification of human PDAC samples (n = 961)
based on high and low pPDGFRb and p53
expression levels. The chi-square test was per-
formed (p = 0.009). p53 and pPDGFRb levels were
assessed by immunofluorescence (IHC) and
scored using a relative scale from 0 to 3.
(E) Kaplan-Meier survival curves of colorectal
cancer patients (clinical variable = DFS) as a
function of PDGFRb-high versus PDGFRb-low
expressing tumors.
(F) Box plot of PDGFRb expression versus tumor
grade of colon tumors (n = 290). Data presented as
mean ± SD.
See also Figure S6.the high disease burden in the pancreas was the primary cause
of death (Figures 6C and S5C).
However, imatinib induced a striking reduction in the occur-
rence of metastasis. The incidence of metastasis was 92% in
vehicle-treated animals compared to 15% in mice treated
with imatinib, as assessed by macroscopic examination and
confirmed by histopathological analyses (c2 test, p < 0.0001)
(Figures 6D and S5D). The antimetastatic effect was observed
across several organs, such as liver, peritoneum, and lung (Fig-
ures 6E and 6F). As expected, imatinib was able to effectively
inhibit PDGFRb activity in primary tumors based on reduced
levels of phospho-PDGFRb in the tumor cells (Figures 6G and
S5E). Together, these data suggest that by inhibiting the kinase
activity of PDGFRb, imatinib significantly diminishes the meta-
static potential of pancreatic cancer cells.
PDGFRb Expression Correlates with Disease-free
Survival in Human Pancreatic, Colorectal, and Ovarian
Cancer Patients
To investigate the clinical significance of PDGFRb expression,
we examined whether upregulation of this gene is correlated390 Cell 157, 382–394, April 10, 2014 ª2014 Elsevier Inc.with prognosis or with the clinicopatho-
logical characteristics of PDACs in pa-
tients. To avoid confounding signals
from the tumor stroma, PDGFRb mRNA
levels were assessed in tumor samples
with high purity score. Strikingly, we
observed that pancreatic cancer patients
with tumors expressing high levels of
PDGFRb showed a poor disease-freesurvival and hence shorter time to relapse, including metastases
in distant organs (p = 0.019) (Figure 7A). Additionally, PDGFRb
expression levels were significantly elevated in late-stage
PDAC as compared to the earlier stages (Figure 7B). Patients
with high PDGFRb levels also displayed an increase in tumor
cells invading the vascular space, another clinicopathological
characteristic of tumor dissemination (Figure 7C).
Next, we tested whether PDGFRb levels correlate with the
status of p53 by analyzing a panel of PDAC tissue microarrays
(TMAs). Of importance, we observed significantly higher levels
of activated PDGFRb in those tumors that showed an accumula-
tion of p53 (p = 0.009), which generally represents tumors with
p53 mutation (Oren and Rotter, 2010) (Figures 7D and S6A).
These data confirmed results obtained with mice and under-
score a role of mutant p53 in regulating the PDGFRb signaling
in human pancreatic cancer.
Other tumor types for which p53 mutations are predictive of
metastatic disease are colorectal and ovarian cancer (Russo
et al., 2005; Levesque et al., 1995). Thus, we analyzed the clinical
significance of PDGFRb in these cancer types and found that
levels of PDGFRb significantly stratified colorectal and ovarian
tumor patients into two distinct cohorts. Patients with tumors
expressing low PDGFRb levels exhibit a lower probability to
form metastases compared to patients with PDGFRb high-
expressing tumors (p = 0.003 and p < 0.0001) (Figures 7E and
S6C). As in PDAC, a significant increase in PDGFRb expression
was observed in higher-stage colorectal cancers (Figure 7F). In
addition to PDGFRb, our mutant p53 gene signature significantly
scored as a prognostic marker in colorectal and ovarian tumor
patients (top 40 genes upregulated in KPC cells; Figure 2C; Table
S1). When we analyzed the three genes that scored in our inva-
sion assay screen, we found that the PDGFRB gene was the
strongest predictor for the probability to develop metastasis in
colorectal and ovarian cancer patients (Figures S6B and S6C).
In summary, consistent with our functional studies, elevated
PDGFRb expression correlated significantly with the status of
p53, higher tumor stage, and a poorer disease-free survival
rate in pancreatic, colorectal, and ovarian cancer patients.
DISCUSSION
Mutations that occur in the p53 tumor suppressor inactivate
wild-type p53 functions but can also produce ‘‘gain-of-function’’
oncogenic properties that can contribute to cell proliferation,
survival, and metastasis. Here, we explored the phenotypic
effects of mutant p53 in pancreatic cancer and showed that
the sustained expression of the mutant p53 allele is necessary
to maintain the invasive phenotype of PDAC cells by increasing
the expression of PDGFRb. These results have several ramifica-
tions for our understanding of mutant p53 action as well as the
behavior and potential treatment of pancreatic cancer.
Signaling through PDGFRb contributes to multiple tumor-
associated processes, including cell invasion and metastasis.
Given the generally restricted expression of PDGFRb to mesen-
chymal cell types, most of the oncogenic properties of PDGFRb
are thought to reflect paracrine effects of tumor cell-secreted
PDGF. Indeed, previous work on the role of PDGFRb in carci-
noma progression andmetastasis suggests that PDGFRbmainly
elicits responses in the tumor stroma by promoting tumor angio-
genesis (Pietras et al., 2003; Cao et al., 2004). In contrast, our
study provides evidence for tumor cell-specific expression of
PDGFRb in promoting metastasis. We show that genetic or
pharmacological inhibition of PDGFRb in the pancreatic cancer
cells themselves dramatically reduces their invasive and meta-
static potential and that treatment of mice harboring genetic
and histologically relevant tumors prevents metastatic spread
in vivo. Together, our data indicate that pancreatic tumor cells
expressing mutant p53 not only synthesize PDGF but also upre-
gulate PDGFRb, leading to a tumor autocrine, cell-autonomous
effect.
Though increases in PDGFRb expression were necessary and
sufficient to mediate mutant p53 effects in our model, we identi-
fied at least two additional genes (SNED1 and SLC40A1) that
also contribute to the invasive phenotype through yet unknown
mechanisms. Studies in other systems, primarily breast cancer,
have suggested that CXCR4, cyclin-G2, and the mevalonate
pathway are important mediators of the prometastatic activities
of mutant p53 (Mehta et al., 2007; Adorno et al., 2009; Freed-
Pastor et al., 2012). In addition, mutant p53 has also been re-ported to drive invasion by regulating several miRNAs, such as
miR155 and miR130b (Neilsen et al., 2013; Dong et al., 2013).
In agreement, we found that miR155 is positively regulated by
mutant p53 in KPC cells and can promote metastasis in our
model (data not shown); however, in contrast to a previous report
(Su et al., 2010), no effects on DICER expression were observed,
arguing that in pancreatic cancer the mutant p53-associated
changes in microRNA expression and metastasis are DICER
independent. Additionally, miR34a expression levels were not
dependent on p53 status in our system (data not shown), even
though this miRNA acts as negative regulator of PDGFRb in
lung cancer (Garofalo et al., 2013). Regardless, as for wild-type
p53, mutant p53 exerts effects through the regulation of multiple
genes rather than by modulating a single signaling pathway.
Most of our understanding of how mutant p53 mediates its
oncogenic activity has been derived from exploring the conse-
quences of the physical interaction between the mutant protein
and the p53 family members, p63 and p73. Whereas the mutant
p53-p63 interaction modulates the expression of p63 target
genes to enhance invasion and metastasis (Adorno et al.,
2009; Muller et al., 2009), how p53-p73 interactions produce
similar outcomes is poorly understood. Here, we show that
mutant p53 enhances pancreatic cancer cell metastasis by
modulating p73 and its interaction with the transcriptional acti-
vator NF-Y. This model is consistent with previous studies
showing that (1) loss of p73 in a p53 null background might be
functionally equivalent to the expression of mutant p53 (Lang
et al., 2004); (2) aberrant transcriptional regulation by mutant
p53 is mediated through the transcriptional activator NF-Y (Di
Agostino et al., 2006); and (3) mutant p53 promotes recycling
of receptor tyrosine kinases to initiate invasion (Muller et al.,
2009).Whether structurally distinct p53mutants enhancemetas-
tasis to the same extent and through the same mechanism
remains unclear, and certainly most truncating mutants arising
from the nonsense mutations occurring in a fraction of pancreas
cancers are predicted to behave as if p53 null. Still, in our study
both conformational (e.g., R175H) and structural mutants (e.g.,
R273H) were capable of inducing PDGFRB through a similar
mechanism.
Questions remain as to how the mutant p53/p73/NF-Y regula-
tory axis acts mechanistically. For instance, it remains unclear
whether p73 acts to suppress the transactivation capacity of
NF-Y or whether it sequesters the activator and prevents its
binding to the PDGFRB promoter. Even though our results indi-
cate that p73 overexpression hampers the ability of NF-Y to bind
to the PDGFRB promoter, further studies will be required to
distinguish between mechanisms. In addition, we noted slightly
stronger induction of PDGFRB transcription as well as higher
levels of invasion upon overexpression of mutant p53 compared
to depletion of p73, indicating that mutant p53 may exert
additional regulatory effects on PDGFRb expression. Although
studies suggest that mutant p53 can directly bind to NF-Y to
regulate its transcriptional activity (Di Agostino et al., 2006), we
failed to observe any physical interaction between mutant p53
and NF-Y in our cells. The discrepancy could reflect different
extraction conditions or biological settings, because the mutant
p53/NF-Y interaction has been shown to occur upon DNA
damage (Liu et al., 2011).Cell 157, 382–394, April 10, 2014 ª2014 Elsevier Inc. 391
Mutations in KRAS, p53, CDKN2A, BRCA2, and SMAD4
define the genetic landscape of PDAC; however, it remains
unclear how each mutation contributes to the malignant evolu-
tion of this aggressive disease. We present evidence for a crucial
role of mutant p53 in metastasis formation, which supports the
attractive concept of targeting its gain-of-function activities to
limit cancer cell dissemination and metastasis. However, mutant
p53 is neither a targetable cell-surface protein nor a druggable
enzyme (Levine and Oren, 2009), and novel therapeutic modal-
ities, such as RNAi or restoring wild-type p53 conformations,
have yet to show efficacy in clinical studies (Lehmann and Pie-
tenpol, 2012). Hence, targeting downstream pathways or genes
that mediate the activity of mutant p53, such as PDGFRb, pose
an alternative treatment strategy.
Owing to the early metastatic spread of pancreatic cancer,
widespread use of PDGFRb inhibitors might require advances
in early detection or combination with other therapies. Nonethe-
less, our study suggests that PDGFRb inhibition might prove
immediately useful in pancreatic patients harboring p53
missense mutations either before (neoadjuvant) or after surgical
resection (adjuvant) of localized disease (10%–15% of PDAC
cases), in patients with locally advanced inoperable nonmeta-
static disease (30% of PDAC cases) or as a preventative
approach in patients with familial predisposition to cancer
development. Moreover, PDGFRb inhibition as a therapeutic
approach could be extended to other metastatic cancer types,
e.g., colorectal, where the disease is often diagnosed before
tumor cell dissemination.
High levels of PDGFRb expression have recently been asso-
ciated with tumor recurrence in primary colorectal cancer,
another gastrointestinal tumor in which p53 is frequently
mutated (Steller et al., 2013). Accordingly, we noted correlations
between elevated PDGFRb levels, more-advanced tumor stage,
and poorer disease-free survival in pancreatic, as well as colo-
rectal and ovarian, cancer patients. These results indicate that
PDGFRb levels might be used as a prognostic biomarker for
cancer progression and eventually be used in conjunction with
p53 to identify patient cohortsmost likely to respond to therapies
targeting this axis. Although further studies will be required to
explore this notion, pharmacological inhibition of PDGFRb with
the tyrosine kinase inhibitor imatinib, in combination with stan-
dard chemotherapy, has shown promise in treating metastatic
colorectal cancer patients (Hoehler et al., 2013).
In summary, we describe a gain-of-function activity of mutant
p53 that promotes invasion and metastasis through increasing
PDGFRB transcription and reverting the repressive function of
the p73/NF-Y complex. While other activities of mutant p53 on
cell behavior and survival exist (Freed-Pastor and Prives,
2012), our study provides a detailed molecular understanding
of at least one aspect of the invasive behavior of cells expressing
mutant p53 and offers a potential target for therapy that might
interfere with this activity.EXPERIMENTAL PROCEDURES
Wound Healing and Invasion Assays
Wound healing and three-dimensional invasion assays were conducted as
previously described (Goulimari et al., 2005; Kitzing et al., 2007). In brief, inva-392 Cell 157, 382–394, April 10, 2014 ª2014 Elsevier Inc.sion assays were carried out in 24-well transwell inserts, lined with collagen
type 1, and cells were seeded on the inverted inserts.
Immunostaining and Microscopy
Invasion assay inserts were fixed using 4% formaldehyde before confocal
microscopy (PerkinElmer Spinning Disk) was conducted. Images were
analyzed using Imaris software.
qRT-PCR
Real-time PCRwas carried out in triplicate using SYBRGreen PCRMaster Mix
on the ViiA 7 Real-Time PCR System.
RNA Sequencing and Data Analysis
Directional (stranded) libraries for paired-end sequencing of KPC cells were
conducted on the Illumina platform. Differential expression analysis for
sequence count data (fragments per kilobase of transcript per million mapped
reads [FPKM] values) was conducted using DESeq.
PDGFRb Luciferase Reporter Assay
Cells were transiently transfected with expression plasmid, reporter plasmid,
and renilla luciferase vector. After 36 hr, firefly luciferase and renilla activities
were measured on a Varioskan Flash Multimode Reader.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation was performed as previously described
(Beckerman et al. 2009). In brief, Protein A/G Sepharose beads conjugated
to anti-NF-YB antibody were used to immunoprecipitate NF-YB from whole
cell lysates. Quantitative ChIP was carried out on an ABI StepOne Plus using
SYBR green dye.
Mouse Studies
All animal experiments were performed in accordance with a protocol
approved by the Memorial Sloan-Kettering Institutional Animal Care and Use
Committee.
Human Data Sets
Gene expression data and survival analyses of ovarian, colorectal, and
pancreatic cancer patients with annotated clinical outcomes were down-
loaded from the Gene Expression Omnibus database (GSE50827, GSE9899,
GSE17537, and GSE28735). For survival analyses, gene expression data
were clustered into groups using kmeans, and Kaplan-Meier analyses was
performed. Significance for these plots was determined using the log rank test.
For further details, please refer to the Extended Experimental Procedures.
ACCESSION NUMBERS
The Sequence Read Archive (SRA) accession number of the RNA sequencing
data reported in this paper is SRP033333.
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figures, and one table and can be found with this article online at http://dx.
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